We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BD Buys TVA Medical, To Provide Minimally Invasive Procedure
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) , also known as BD, recently completed the acquisition of Texas-based TVA Medical. Financial terms of the deal have been kept under wraps.
Post the announcement, shares of BD inched down 0.04% to $244.55.
Per management, the transaction is not expected to be accretive to BD’s financial results in fiscal 2018 or 2019.
In the past year, the company’s shares have rallied 24.5% compared with the industry’s rise of 8.2%.
The stock carries a Zacks Rank #3 (Hold).
Coming back to the news, TVA Medical develops minimally invasive vascular access solutions for patients with chronic kidney disease who require hemodialysis.
The recent integration is likely to boost BD’s core Medical segment. Additionally, the buyout will enable BD to provide TVA’s flagship everlinQ endoAVF system. The everlinQ endoAVF, which received a De Novo marketing clearance from the FDA, is used for hemodialysis without relying on open surgery.
The acquisition will allow BD to serve physicians and patients by providing minimally invasive procedures for patients with chronic kidney disease.
Market Prospects
Management opines that there are more than 440,000 patients with End-Stage Renal Disease (ESRD) who depend on hemodialysis in the United States.
Moreover, per research by MarketsandMarkets, the U.S. market for minimally invasive surgical devices is projected to reach $21.47 billion by 2021 from $13.89 billion in 2016, at a CAGR of 9.1%.
Benefits of minimally invasive surgeries compared with traditional open surgeriesa well asreduction in healthcare costs and timedrive growth in the market.
Hence, BD’s latest move is a timely and strategic one.
MedTech’s Minimally-Invasive Breakaway
Minimally-invasive surgery involves fewer incisions to reduce trauma for patients. Of late, the U.S. MedTech space has been witnessing increased usage of the surgical procedure.
BD is one of the major global MedTech players that has been raking huge profits from its minimally invasive procedures. The company’s flagship V. Mueller and Snowden-Pencer laparoscopic instruments are among the most advanced surgical instruments available in the market.
Intuitive Surgical’s (ISRG - Free Report) coveted da Vinci platform deserves a special mention here. The system is powered with robotic technology that enables surgeonsto make smaller and precise movements.
Also, Stryker Corporation’s (SYK - Free Report) robotic-arm assisted Mako surgery platform facilitates advanced joint replacement surgery solutions.
Want More From the Industry?
A better-ranked stock from the Medical Dental Supplies space is Henry Schein, Inc. (HSIC - Free Report) .
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
BD Buys TVA Medical, To Provide Minimally Invasive Procedure
Becton, Dickinson and Company (BDX - Free Report) , also known as BD, recently completed the acquisition of Texas-based TVA Medical. Financial terms of the deal have been kept under wraps.
Post the announcement, shares of BD inched down 0.04% to $244.55.
Per management, the transaction is not expected to be accretive to BD’s financial results in fiscal 2018 or 2019.
In the past year, the company’s shares have rallied 24.5% compared with the industry’s rise of 8.2%.
The stock carries a Zacks Rank #3 (Hold).
Coming back to the news, TVA Medical develops minimally invasive vascular access solutions for patients with chronic kidney disease who require hemodialysis.
The recent integration is likely to boost BD’s core Medical segment. Additionally, the buyout will enable BD to provide TVA’s flagship everlinQ endoAVF system. The everlinQ endoAVF, which received a De Novo marketing clearance from the FDA, is used for hemodialysis without relying on open surgery.
The acquisition will allow BD to serve physicians and patients by providing minimally invasive procedures for patients with chronic kidney disease.
Market Prospects
Management opines that there are more than 440,000 patients with End-Stage Renal Disease (ESRD) who depend on hemodialysis in the United States.
Moreover, per research by MarketsandMarkets, the U.S. market for minimally invasive surgical devices is projected to reach $21.47 billion by 2021 from $13.89 billion in 2016, at a CAGR of 9.1%.
Benefits of minimally invasive surgeries compared with traditional open surgeriesa well asreduction in healthcare costs and timedrive growth in the market.
Hence, BD’s latest move is a timely and strategic one.
MedTech’s Minimally-Invasive Breakaway
Minimally-invasive surgery involves fewer incisions to reduce trauma for patients. Of late, the U.S. MedTech space has been witnessing increased usage of the surgical procedure.
BD is one of the major global MedTech players that has been raking huge profits from its minimally invasive procedures. The company’s flagship V. Mueller and Snowden-Pencer laparoscopic instruments are among the most advanced surgical instruments available in the market.
Intuitive Surgical’s (ISRG - Free Report) coveted da Vinci platform deserves a special mention here. The system is powered with robotic technology that enables surgeonsto make smaller and precise movements.
Also, Stryker Corporation’s (SYK - Free Report) robotic-arm assisted Mako surgery platform facilitates advanced joint replacement surgery solutions.
Want More From the Industry?
A better-ranked stock from the Medical Dental Supplies space is Henry Schein, Inc. (HSIC - Free Report) .
Henry Schein's gains in the United States as well as overseas raise optimism. The stock carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>